Injurious Falls Common in Last Years of Life With COPD
By Lori Solomon HealthDay Reporter
THURSDAY, Jan. 23, 2025 -- Injurious falls are common among people with chronic obstructive pulmonary disease (COPD) in the two years before death, with some medications tied to higher fall risk, according to a study published online Oct. 25 in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.
Cara L. McDermott, Pharm.D., Ph.D., from Duke University in Durham, North Carolina, and colleagues retrospectively analyzed linked electronic health records and death certificates to determine fall risk for 8,204 adults aged 40 years and older with COPD who died between 2014 and 2018.
The researchers found that 30 percent of decedents with COPD had an injurious fall in the two years before death, and use of fall risk-increasing drugs (FRIDs) was common (65 percent). Compared with individuals without a fall, a higher percentage of patients with falls received prescriptions for anticonvulsants (35 versus 26 percent), antipsychotics (24 versus 13 percent), atypical antidepressants (28 versus 19 percent), and tricyclic antidepressants (10 versus 5 percent). When adjusting for confounders, FRID burden was associated with greater odds of injurious falls (odds ratio, 1.07).
"Our findings highlight an opportunity for collaboration between pharmacists, pulmonologists, and patients to develop new processes to potentially deprescribe and optimize the use of FRIDs among patients with COPD to increase safety," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-24 06:00
Read more
- FDA Proposes New Front-of-Package Food Labels
- FDA Approves Gemtesa for Overactive Bladder in Men With BPH
- Phone App May Help Treat Opioid Use Disorder, Data Suggests
- Vaccination Does Not Impact Long COVID Neurological Symptoms
- FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
- Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions